The use of neoadjuvant and adjuvant chemotherapy for the treatment of muscle-invasive bladder cancer is associated with a survival benefit in the general population, and may be underutilized.
Higher hospital charge and increased length of stay for patients aged 80 years and older post-resection
High intake of saturated fats is associated with increased risk of certain subtypes of breast cancer.
Palonosetron and netupitant combo showed superior efficacy in controlling nausea and vomiting compared with palonosetron alone.
In a phase 1 study, the potent ALK inhibitor shows promise for treating NSCLC.
R.M. is a 58-year-old male recently diagnosed with stage IV pancreatic adenocarcinoma (Slide 1). He is a mechanical engineer ...
J.W. is a 55-year-old woman recently admitted to the hospital for worsening shortness of breath (Slide 1).
Relevant Medical History
Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.
ChemotherapyAdvisor.com Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.
Barbara Ann Burtness, MD
Steven Cohen, MD
E. David Crawford, MD
Don S. Dizon, MD, FACP
Jeffrey M. Farma, MD
Edith A. Perez, MD
Neal D. Shore, MD, FACS
Mark A. Socinski, MD
Martin Tallman, MD
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|